COVID-19 has ravaged the world for nearly a year. At a press conference this afternoon (11th), the Hong Kong government announced that it had pre-ordered two vaccines, including a vaccine jointly developed by Pfizer, BioNTech, and Shanghai Fosun Pharma. However, the government issued a manuscript at about 11 o’clock late at night. The “report” means that the vaccine for Hong Kong was jointly developed by Fosun and BioNTech.
Pfizer Pharmaceuticals of the United States is BioNTech’s partner in China, Hong Kong, Macau, and other regions. Members of the government advisory panel and specialist doctors expect that the Hong Kong version collectively referred to as “Pfizer Vaccine” will be produced in China.
As for another Wufei vaccine that will be supplied to Hong Kong and developed by a Chinese-funded “Kexing Holding Biotechnology Company,” the first batch of 1 million doses will arrive in Hong Kong as soon as next month. The third phase of the clinical research report has not yet been published. Experts believe that Hong Kong The government should wait for the report to review the side effects and risks before arranging patient vaccination.
The Hong Kong government announced today (11th) that it has signed a “pre-purchase agreement” with three vaccine research and development pharmaceutical companies to purchase a total of more than 20 million doses of vaccines, including Kexing Holdings Biotechnology Company, Fosun Pharma/BioNTech, and the University of Oxford AstraZeneca co-developed a vaccine.
Liang Zichao and Xu Shuchang: The vaccine formula of convenient logistics material produced in Guangdong is the same
At today’s press conference, Carrie Lam said that the second inbound vaccine was jointly developed by Pfizer, Shanghai Fosun, and BioNTech. However, when the government issued a manuscript in the evening, it “revised” that Fosun and BioNTech jointly developed it. Pfizer is BioNTech in China. Hong Kong, Macau, and partners outside of Taiwan. After the “change of mouth,” the relevant vaccine’s origin has also become a mystery.
Xu Shuang, a government expert consultant and chair professor of the Department of Respiratory Medicine at CUHK, pointed out that the production lines of BioNTech and Pfizer mainly cover Europe and North America. If Asia wants to buy vaccines, it needs to find “outsourcers,” and in Asia, Fosun Pharma will serve as the production line…
He explained that the vaccine needs to be stored at the same time as dry ice, but dry ice can only last for more than 20 hours. If sent from Europe and the United States to Hong Kong, it will be “a good hurry.” It is said that Star Pharma has factories in Shanghai and Guangdong. Fosun Pharma produces all BioNTech vaccines in China.
Whether the vaccine produced by Fosun will be different from Europe and the United States, Xu Shuchang pointed out that it may not be the same due to outsourcing production or supporting facilities such as factories. Still, the vaccine formula is believed to be the same.
Respiratory specialist Liang Zichao also believes that because BioNTech’s vaccine must be stored at -70 degrees Celsius, it is believed that logistics and storage are a big challenge. Liang Zichao estimates that if Fosun is responsible for producing vaccines in Guangdong, the cost and delivery technology will be greatly reduced. “Fosun will produce (vaccine) in the Guangdong plant as an agent, and the flight distance will be short. As the dry ice storage time is not possible, It’s too long, and it will be quite a hurry to send from Europe to Hong Kong, and the temperature may not be guaranteed.”
King did not have the third phase clinical research report.
Checking the data shows that for the vaccine developed by Kexing, the Phase III clinical research report has not yet been announced, nor has the vaccine’s effective protection been announced to the outside world. It only means that the “antibody positive conversion rate” of vaccinators is 97%; Fosun/BioNTech and AstraZeneca vaccines have announced effective protections of 95% and 70%, respectively.
If there is no third phase clinical research report for the vaccine, will it pose a safety concern? Kong Fanyi, director of the Department of Infectious Diseases of the Department of Internal Medicine at the University of Hong Kong, told The Position that if it is a “live-attenuated vaccine,” it is not suitable for people with immune system problems. For example, patients with lupus erythematosus may have allergies and other adverse reactions. But Kexing’s vaccine is an “inactivated vaccine,” so there should be no related problems.
Kong Fanyi: Hong Kong’s low infection rate can be vaccinated in the third report
However, Kong Fanyi still believes that the third phase of the report will be released before Hong Kong experts can learn more about which patients are not suitable for vaccination and reduce the chance of side effects. He estimated that Kexing would publish the third phase research report in international journals within one month. Therefore, the Hong Kong government should wait a little while before starting preparations for the vaccination plan in February next year and start arranging for Hong Kong people’s vaccination in March.
When asked why European and American countries had arranged for people to be vaccinated with vaccines from different pharmaceutical companies before the third phase of the report, Kong Fanyi explained that due to the unsatisfactory anti-epidemic situation in European and American countries, it is urgent to rely on vaccines to fight the epidemic. “There is indeed a risk. Yes, but they estimate that if they are not vaccinated, more patients may be infected with pneumonia, and the death rate will be higher.”
He continued that compared with European and American countries, Hong Kong’s infection rate is low, and protection awareness is high. “Although there are 100 symptoms per day, it is less important than in foreign countries. Most critically ill patients have already received treatment early, which helps reduce the risk. And mortality.” He reiterated that the Hong Kong government does not need to wait for the vaccine to be launched on the market. It can wait until Kexing publishes the third report before launching the vaccine.
Also, Carrie Lam said today that citizens could not choose which vaccine to get. “You can say that it is a free choice.” Kong Fanyi estimates that the statement is only Lam Cheng’s preliminary thoughts, “It means that people with normal health cannot be chosen, but if it is a patient or the elderly, it can be chosen by the doctor.”
Yuan Guoyong: Vaccination must be voluntary
Government expert consultant and Chair Professor of the Department of Microbiology of the University of Hong Kong, Yuan Guoyong, said in response to the “Stance News” inquiry that whether the vaccine is safe and suitable for vaccination still needs to review the Phase III clinical research report.
When the vaccine should be vaccinated, Yuan Guoyong reiterated that he had estimated earlier that the vaccine would be available in Hong Kong as early as June next year. Still, it will not be available to all Hong Kong citizens until the end of next year. He also pointed out that vaccination must be voluntary, and citizens cannot be forced to receive emergency approved vaccines.